This mechanism of cancer cell inhibition mainly affects cancer types such as breast, prostate and bladder cancers and leukemias, which involve an abundance of transferrin receptors and the upregulated production of ribonucleotide reductase [18,19,185,186,187,188]. Here, TFRC is linked to leukemia.